| NCT ID | NCT06230406 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Policlinico S. Donato |
| Condition | Atherosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 12 participants |
| Start Date | 2023-09-28 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12 participants in total. It began in 2023-09-28 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the progressive accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries, forming the so-called "atherosclerotic plaques". The formation process of these lesions is different depending on the age, genetics and physiological state of the individual affected. Furthermore, behavioral factors and the lifestyle of each individual play a key role, which can lead to the presence of a series of pro-atherosclerotic pathologies and risk factors, such as in particular systemic arterial hypertension, dyslipidemia, hyperglycemia and cigarette smoking. However, the precise molecular mechanisms underlying this pathogenetic process are still under investigation. The results of a study conducted in the past in collaboration between the U.O. have recently been published. of Vascular Surgery and the laboratory of Dr. I. Zucchi of the Institute of Biomedical Technologies of the CNR of Milan Segrate (Protocol GEMMA NUOVA, 16/int/2016), which describes that the overexpression of a newly identified gene (TMEM230) it may have a role in the formation of atherosclerotic vascular disorders, but it is still unclear how the expression of this gene is modulated in vivo. Knowledge of these factors would increase the knowledge of the molecular mechanisms underlying atherosclerosis and could represent a possible target for prevention and targeted pharmacological treatment, with consequent potential reduction in disability or mortality from cardiovascular diseases.
Eligibility Criteria
Inclusion Criteria: * adult patients (age \> 18 years) * consent to participate in the study, * patients coming to the Vascular Surgery Unit I of the IRCCS Policlinico San Donato for a vascular pathology of the arterial or venous district worthy of surgical treatment. Exclusion Criteria: * minor patients, * patients who have not given their consent to participate in the study, * patients who have vascular pathologies of the arterial or venous district not susceptible to surgical intervention.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06230406 clinical trial?
This trial is open to participants of all sexes, studying Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06230406 currently recruiting?
Yes, NCT06230406 is actively recruiting participants. Contact the research team at mattia.ricotti@grupposandonato.it for enrollment information.
Where is the NCT06230406 trial being conducted?
This trial is being conducted at San Donato Milanese, Italy.
Who is sponsoring the NCT06230406 clinical trial?
NCT06230406 is sponsored by IRCCS Policlinico S. Donato. The trial plans to enroll 12 participants.